Apotex Inc.

Apotex Inc. is a privately held Canadian pharmaceutical company founded in 1974. Headquartered in Toronto, Ontario, it is the largest producer of generic drugs in Canada. As of 2023, the company employed approximately 8,000 people and had annual sales of around CA$3.9 billion. Since April 2023, Apotex has been owned by the private equity firm SK Capital Partners. There have been reports in early 2026 that the company is considering an initial public offering.

Apotex is an operating company that develops, manufactures, and distributes a wide range of pharmaceutical products. Its portfolio includes over 300 generic drugs in thousands of different dosages and formats. The company's products address a variety of health conditions, including cancer, diabetes, cardiovascular disease, and infections. In addition to generic pharmaceuticals, Apotex is also involved in biosimilars, active pharmaceutical ingredients (APIs), and consumer health products. The company exports its products to over 115 countries.

As a major generic drug manufacturer, Apotex is frequently involved in patent litigation, often challenging patents held by brand-name pharmaceutical companies to bring more affordable generic versions of drugs to market. The company's litigation posture is primarily that of an active challenger of existing patents. The single tracked case, where Apotex is the plaintiff, is consistent with this strategy. This case, filed in April 2026 at the Patent Trial and Appeal Board (PTAB), is a proceeding against Soleno Therapeutics Inc. The PTAB is a common venue for generic manufacturers to challenge the validity of patents.